

Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over

Information for the public

Published: 15 April 2025

www.nice.org.uk

Ruxolitinib (Jakavi) is available on the NHS as a possible treatment for acute graft versus host disease that has not responded well enough to corticosteroids in people 12 years and over.

Is this treatment right for me or my child?

Your healthcare professionals should give you clear information, talk with you about your or your child's options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my or my child's day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment or do not want my child to have the treatment? Are there other treatments available?

Information and support

The [NHS webpage on on stem cell transplant](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Anthony Nolan Trust](#), 0303 303 0303
- [Leukaemia Care](#), 08088 010 444

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6938-8